Beyond the Delivery Room: Data, Doulas, and Patient-Centered OB-GYN
MD Newsline
In this episode of MD Newsline, Dr. Dillon Bannis, an OB-GYN practitioner based in the South Side of Chicago, shares his insights on the evolving challenges and innovations in obstetric and gynecological care. Dr. Bannis explores how listening, collaboration, and technology are reshaping the patient experience—from prenatal care and delivery practices to addressing health disparities and integrating AI into medicine.
With a strong emphasis on patient-centered communication, interdisciplinary col
info_outline
Infant Feeding, Early Habits & Childhood Obesity: What Parents Need to Know
MD Newsline
In this episode of MD Newsline, Dr. Wanda Averhart, a general pediatrician and obesity medicine specialist, explores the complex causes and lifelong impacts of childhood obesity, emphasizing how early feeding practices, maternal health, and social disparities shape children's long-term outcomes.
Dr. Averhart provides a comprehensive look at how environmental, cultural, and biological factors contribute to rising obesity rates among children—especially in underrepresented communities. She discuss
info_outline
The Future of Myeloma: Quadruplets, CAR-T & Beyond
MD Newsline
In this episode of MD Newsline, Dr. Shaina A. Rozell, a hematologist-oncologist at Affiliate Oncology in Chicago, Illinois, explores the rapidly advancing field of multiple myeloma treatment. She discusses how quadruplet therapies, MRD monitoring, and novel immunotherapies like bispecific antibodies and CAR-T are transforming outcomes for patients. Dr. Rozell also examines disparities in access to care, the growing role of community practices in clinical trials, and the balance between extending survival
info_outline
HPV Throat Cancer Misdiagnoses And How Technology Shapes ENT Health
MD Newsline
In this episode of MD Newsline, Dr. Tonia L. Farmer, a board-certified otolaryngologist and head & neck surgeon, discusses the gaps in ENT care, the growing impact of HPV-related cancers, and the importance of education and early detection in improving outcomes—particularly for underserved communities. Drawing from years of practice, Dr. Farmer explores how social, behavioral, and environmental factors shape ENT health and shares insights on emerging research and technologies revolutionizing the field.
info_outline
Personalized Approaches to Metabolic Liver Disease and MASH Management
MD Newsline
In this episode of MD Newsline, Dr. Christopher Kaisa, Assistant Professor of Medicine in the Section of Gastroenterology, Hepatology, and Nutrition at the University of Chicago Medicine, provides an in-depth discussion on Metabolic Dysfunction-Associated Steatohepatitis (MASH) and the evolving strategies for its management. He explains the latest non-invasive diagnostic tools, pharmacologic advancements, and the importance of multidisciplinary care in improving outcomes for patients with metabolic liver
info_outline
What's Next in Diabetes Care: New Treatments and Tech Insights
MD Newsline
In this episode of MD Newsline, Dr. Rachael Sood, a diabetes nurse practitioner and certified diabetes care and education specialist from New Orleans, Louisiana, shares her insights from the 85th American Diabetes Association Scientific Sessions. As the founder of The Diabetes Collective, Dr. Sood discusses the evolution of diabetology—a specialized field focused solely on the identification, treatment, and management of diabetes across all patient populations.
info_outline
High-Risk Multiple Myeloma & Personalized Treatment
MD Newsline
In this episode of MD Newsline, Dr. Martin Kaiser, Consultant Hematologist at the Royal Marsden Hospital and Professor of Hematology at the Institute of Cancer Research, London, discusses groundbreaking advances in the diagnosis and management of high-risk multiple myeloma. Drawing insights from the OptiMUM trial and related studies, Dr. Kaiser explores how genetic profiling, long-term treatment intensity, and personalized approaches are transforming patient outcomes. He also examines the challenges of t
info_outline
Clinical Trials vs Real World Practice in Leukemia Treatment
MD Newsline
In this episode of MD Newsline, Dr. Mark R. Litzow, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, discusses the groundbreaking findings from the ECOG-ACRIN E1910 trial and the evolving role of immunotherapy in acute lymphoblastic leukemia (ALL). He explores how real-world evidence complements clinical trials, the challenges of standardizing measurable residual disease (MRD) testing, and the future of personalized treatment strategies in hematologic malignancies.
Dr. Litzow shares deep
info_outline
A New Way to Treat Adrenal Insufficiency with an Insulin Pump
MD Newsline
In this episode of MD Newsline, Dr. Sassan Mirfakhraee, adult endocrinologist and associate professor at the University of Texas Southwestern Medical Center, shares groundbreaking insights into the management of adrenal insufficiency. At the Endocrine 2025 conference, Dr. Mirfakhraee presented his research on utilizing insulin pumps to deliver hydrocortisone—an innovative off-label approach that is showing promising results for patients who remain symptomatic on oral therapy.
He explains how thi
info_outline
Fighting Bone Metastasis in Breast Cancer
MD Newsline
In this episode of MD Newsline, we welcome Dr. Emily Zboril, a PhD candidate at Virginia Commonwealth University, to discuss her groundbreaking research on ER-positive breast cancer with bone metastasis. Emily sheds light on the unique challenges of treating this condition, the role of the bone microenvironment, and how novel therapies like lazophoxifene may change the landscape of care.
She explains how endocrine therapies currently used to block estrogen signaling often worsen bone fragility, leading t
info_outlineIn this episode of MD Newsline, hepatologist Dr. Steven Flamm (Northwestern Medicine) demystifies the spectrum of metabolic-associated fatty liver disease—from the highly prevalent MASLD (metabolic-associated steatotic liver disease) to its inflammatory form, MASH (metabolic-associated steatohepatitis). Dr. Flamm details who is at risk, why only a subset progress to fibrosis and cirrhosis, and how clinicians can intervene early with lifestyle, pharmacologic, and procedural tools. He also reviews the first FDA-approved therapy (resmetirom), the promise of GLP-1 agents, and why cardiovascular and cancer screening remain paramount for these patients.
Episode Highlights:
Defining MASLD and MASH Dr. Flamm explains the reclassification of fatty liver disease into MASLD (metabolic-associated steatotic liver disease) and MASH (metabolic-associated steatohepatitis). MASLD is widespread, affecting nearly 100 million Americans, but only a fraction progress to MASH and fibrosis. Diagnosis relies on imaging for liver fat and biopsy to assess inflammation and fibrosis stage.
Risk Factors and Disease Progression Obesity, type 2 diabetes, and dyslipidemia are the key drivers of MASLD and MASH. Dr. Flamm highlights the importance of early identification and the role of insulin resistance and genetic predisposition in disease progression. He also addresses the need for better awareness of the cardiovascular and oncologic risks associated with fatty liver disease.
Treatment Options and Emerging Therapies Weight loss remains the cornerstone of treatment, with a target of 8–10% reduction in body weight to reverse liver inflammation and fibrosis. Dr. Flamm reviews current options including GLP-1 receptor agonists, bariatric procedures, and the newly approved resmetirom for MASH. He also emphasizes that statins are safe and effective in these patients despite outdated concerns.
Multidisciplinary Management and Patient Monitoring Dr. Flamm outlines a comprehensive care strategy involving endocrinologists, nutritionists, cardiologists, and hepatologists. He recommends regular cardiovascular screening and bi-annual ultrasounds for cirrhotic patients to detect hepatocellular carcinoma early. Patients with alcohol use should be counseled to abstain to prevent further liver damage.
Future Directions in Fatty Liver Research Genetic and gut-liver axis research is paving the way for personalized medicine in MASLD and MASH. Dr. Flamm anticipates more targeted antifibrotic therapies and combination regimens to emerge, transforming the treatment landscape over the next decade.
Key Takeaway:Effective management of MASLD/MASH hinges on early identification of at-risk patients, aggressive control of metabolic drivers, and use of evolving pharmacologic options—while never losing sight of the dominant threats of cardiovascular disease and extra-hepatic cancers.
Resources:Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Steven Flamm https://www.rushu.rush.edu/faculty/steven-flamm-md-faasld-facg
Hosted on Acast. See acast.com/privacy for more information.